Lumicef

Lumicef

brodalumab

Manufacturer:

Kyowa Kirin

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Brodalumab
Indications/Uses
Psoriasis vulgaris in patients w/ inadequate response to phototherapies or other existing systemic therapies (except biologics) & those w/ skin eruptions over 10% or more of BSA; in patients w/ intractable skin eruptions.
Dosage/Direction for Use
SC Adult 1st dose 210 mg, followed by doses 1 wk later, 2 wk later, & once every 2 wk thereafter.
Contraindications
Hypersensitivity, serious infection, active TB.
Special Precautions
Patients w/ infections or suspected infections; history of TB; depression or w/ such a history; history of suicidal ideation or attempt; active Crohn's disease. Possible onset of malignant tumors. Avoid live vaccines & other biologics. Pregnancy. Avoid breastfeeding during treatment. Childn. Elderly.
Adverse Reactions
URTI, nasopharyngitis, headache, arthralgia, pruritus, fatigue, oral candidiasis. Serious infection, decreased neutrophil count, serious hypersensitivity.
MIMS Class
Immunosuppressants
ATC Classification
L04AC12 - brodalumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Lumicef inj 210 mg/1.5 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in